Haloperidol News and Research

RSS

Haloperidol is a typical antipsychotic. It is in the butyrophenone class of antipsychotic medications and has pharmacological effects similar to the phenothiazines.

Depression linked with a specific autoantibody and central nervous system dysfunction in lupus

Systemic lupus erythomatosus (SLE), often simply called lupus, is a complex autoimmune disease marked by joint pain, skin rashes, extreme fatigue, and depression, among other symptoms.

27 Feb 2007

FDA warns consumers about buying medications over the Internet

The Food and Drug Administration (FDA) in the United States has again warned consumers about buying medications over the Internet.

19 Feb 2007

Tetrabenazine cuts down involuntary movements in Huntington's disease

The medication tetrabenazine cut down involuntary movement in patients with Huntington's disease on average by about 25 percent, with many patients experiencing a greater improvement, according to a study in the February 14 issue of the journal Neurology.

17 Feb 2006

Link between cat faeces and schizophrenia

Researchers have found stronger evidence for a link between a parasite in cat faeces and undercooked meat and an increased risk of schizophrenia.

18 Jan 2006

Study of the effects of aripiprazole, olanzapine, quetiapine and risperidone, in elderly patients with dementia

Some newer antipsychotic medications may be associated with a small increased risk of death when used to treat elderly dementia patients, psychiatrists at Johns Hopkins warn.

18 Oct 2005

Commonly used drugs raise the risk of cardiac problems

As many as 15,000 sudden deaths each year in Europe and the U.S., may be caused by drugs commonly prescribed for psychiatric and gut disorders.

11 May 2005

Increased risk of sudden cardiac death from some non-cardiac drugs

Non-cardiac drugs that interfere with the electrical activity controlling the heartbeat are associated with a three-fold risk of sudden cardiac death, according to Dutch research published (Wednesday 11 May) in Europe's leading cardiology journal, the European Heart Journal.

11 May 2005

New antipsychotic drug prevents brain loss in schizophrenia

A new brain imaging study of recently diagnosed schizophrenia patients has found, for the first time, that the loss of gray matter typically experienced by patients can be prevented by one of the new atypical antipsychotic drugs, olanzapine, but not by haloperidol, an older, conventional drug.

4 Apr 2005

Different antipsychotic medications may have different effects on brain volume in patients with first episode of psychosis

After a first psychotic episode, patients who were treated with an atypical antipsychotic medication had less change in brain volume compared with patients treated with a conventional antipsychotic medication, according to an article in the April issue of Archives of General Psychiatry.

4 Apr 2005

FDA has approved Zyprexa, injectable anti-psychotic drug

Physicians have a new fast-acting option for controlling the potentially crippling effects of acute agitation in patients suffering with schizophrenia and bipolar mania. The U.S. Food and Drug Administration (FDA) has approved Zyprexa® IntraMuscular (olanzapine for injection), an injectable form of Lilly's top-selling medication.

30 Mar 2004